

Revision date: 05-Jun-2018 Version: 2.1 Page 1 of 13

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Trade Name: Not applicable Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for seizures and epilepsy

Details of the Supplier of the Safety Data Sheet Greenstone LLC 100 Route 206 North Peapack, NJ 07977 800-435-7095

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture GHS - Classification

Reproductive Toxicity: Category 1B Carcinogenicity: Category 2

Label Elements

Signal Word: Danger

Hazard Statements: H360D - May damage the unborn child H351 - Suspected of causing cancer

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

Page 2 of 13

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Ethyl alcohol (ethanol)	64-17-5	200-578-6	Flam. Liq. 2 (H225)	< 1
Glycerin, USP	56-81-5	200-289-5	Not Listed	*
Phenytoin	57-41-0	200-328-6	Acute Tox 4 (H302) Carc. 2 (H351) Repr 1B (H360D)	2-2.5
Sucrose	57-50-1	200-334-9	Not Listed	*

Ingredient	CAS Number	EU	GHS Classification	%
		EINECS/ELINCS		
		List		
Carboxymethylcellulose sodium	9004-32-4	Not Listed	Not Listed	*
Citric acid, anhydrous	77-92-9	201-069-1	Not Listed	*
Concentrated orange oil	8008-57-9	Not Listed	Not Listed	*
FD&C Yellow No. 6; (Sunset yellow)	2783-94-0	220-491-7	Not Listed	*
Imitation banana oil	NOT ASSIGNED	Not Listed	Not Listed	*
Magnesium aluminum silicate	1327-43-1	215-478-8	Not Listed	*
Polysorbate 40	9005-66-7	Not Listed	Not Listed	*
Purified water	7732-18-5	231-791-2	Not Listed	*
Sodium benzoate	532-32-1	208-534-8	Not Listed	*
Vanillin	121-33-5	204-465-2	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has

been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

None known

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on p

Exposure:

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

Medical Conditions

Aggravated by Exposure:

Page 3 of 13

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation of toxic gases is possible during heating or fire.

Products:

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

Collecting: area thoroughly.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

Large Spills: situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Use with adequate ventilation. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

Page 4 of 13

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Ethyl alcohol (ethanol)

ACGIH Threshold Limit Value (STEL) Australia TWA	1000 ppm 1000 ppm
	1880 mg/m ³
Austria OEL - MAKs	1000 ppm
	1900 mg/m ³
Belgium OEL - TWA	1000 ppm
- · · ·· -···	1907 mg/m ³
Bulgaria OEL - TWA	1000 mg/m ³
Czech Republic OEL - TWA	1000 mg/m ³
Denmark OEL - TWA	1000 ppm 1900 mg/m ³
Estonia OEL - TWA	500 ppm
EStoriia OEL - TWA	1000 mg/m ³
Finland OEL - TWA	1000 mg/m
Timana GEE TWA	1900 mg/m ³
France OEL - TWA	1000 ppm
	1900 mg/m ³
Germany - TRGS 900 - TWAs	500 ppm
	960 mg/m ³
Germany (DFG) - MAK	500 ppm
0 051 5111	960 mg/m ³
Greece OEL - TWA	1000 ppm
Hungary OEL - TWA	1900 mg/m ³ 1900 mg/m ³
Latvia OEL - TWA	1000 mg/m ³
Lithuania OEL - TWA	500 ppm
Littidaliia OLL - I WA	1000 mg/m ³
Netherlands OEL - TWA	260 mg/m ³
OSHA - Final PELS - TWAs:	1000 ppm
	1900 mg/m ³
Poland OEL - TWA	1900 mg/m ³
Portugal OEL - TWA	1000 ppm
Romania OEL - TWA	1000 ppm
	1900 mg/m ³
Slovakia OEL - TWA	500 ppm
Clavenia OEL TWA	960 mg/m ³
Slovenia OEL - TWA	1000 ppm 1900 mg/m ³
Sweden OEL - TWAs	500 ppm
Official OLL - 111/13	1000 mg/m ³
	··· ·

Glycerin, USP

10 mg/m ³
10 mg/m ³
10 mg/m ³
10 mg/m ³
20 mg/m ³
10 mg/m ³
200 mg/m ³

Page 5 of 13

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

 Greece OEL - TWA
 10 mg/m³

 Ireland OEL - TWAs
 10 mg/m³

 OSHA - Final PELS - TWAs:
 15 mg/m³

 Poland OEL - TWA
 10 mg/m³

 Portugal OEL - TWA
 10 mg/m³

 Spain OEL - TWA
 10 mg/m³

Phenytoin

Manufacturer OEL: 400ug/m³

Sucrose

ACGIH Threshold Limit Value (TWA) 10 mg/m³ 10 mg/m³ **Australia TWA** 10 mg/m³ **Belgium OEL - TWA Bulgaria OEL - TWA** 10.0 mg/m³ 10 mg/m³ Estonia OEL - TWA France OEL - TWA 10 mg/m³ 10 ma/m³ **Ireland OEL - TWAs** Latvia OEL - TWA 5 mg/m³ Lithuania OEL - TWA 10 mg/m³ **OSHA - Final PELS - TWAs:** 15 mg/m³ Portugal OEL - TWA 10 mg/m³ Slovakia OEL - TWA 6 mg/m³ 10 mg/m³ Spain OEL - TWA

Analytical Method: Exposure Controls Engineering Controls: Analytical method available for Phenytoin. Contact Pfizer Inc for further information.

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

Molecular Weight:

Page 6 of 13

Mixture

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid suspension Color: Orange

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture

Solvent Solubility:
Water Solubility:
PH:
No data available
No data available
No data available.
No data available.
No data available.
No data available
No data available
Partition Coefficient: (Method, pH, Endpoint, Value)

Sodium benzoate No data available

Carboxymethylcellulose sodium

No data available **Polysorbate 40**No data available

Sucrose

No data available

Ethyl alcohol (ethanol)

No data available

Vanillin

No data available

FD&C Yellow No. 6; (Sunset yellow)

No data available

Purified water

No data available

Imitation banana oil

No data available

Concentrated orange oil

No data available

Citric acid, anhydrous

No data available **Glycerin. USP**

No data available

Phenytoin

Predicted 7.4 Log D 2.47 **Magnesium aluminum silicate**

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):No data availableVapor Pressure (kPa):No data availableVapor Density (g/ml):No data availableRelative Density:No data availableViscosity:No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

Polymerization:

No data available
No data available
Will not occur

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Short Term: May cause eye irritation (based on components) .

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and

blood forming organs, gastrointestinal system, and liver.

Known Clinical Effects: The most common adverse effects observed with clinical use of phenytoin are lack of appetite,

headache, dizziness, transient nervousness, ataxia, slurred speech, decreased coordination, mental confusion, insomnia, and GI disturbances (nausea, vomiting, and constipation). IV

Page 7 of 13

administration has been associated with hypotension and CNS depression. Mild

hypersensitivity reactions (skin rashes) are common. Effects on blood- forming organs and the liver have occurred rarely. Other less common effects include swollen lymph nodes, sore mouth, and symptoms of dependence/withdrawal. There is an unconfirmed association between the use of anticonvulsants during pregnancy and an increased risk of birth defects. This material has been shown to be secreted in low concentrations in human breast milk.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium benzoate

Rat Oral LD50 4,070 mg/kg Mouse Oral LD50 1600mg/kg

Carboxymethylcellulose sodium

Mouse Oral LD50 > 27,000 mg/kg Rat Oral LD50 27,000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Ethyl alcohol (ethanol)

Mouse Oral LD50 3450 mg/kg Rat Oral LD50 7060mg/kg

Rat Inhalation LC50 10h 20,000ppm

Vanillin

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

11. TOXICOLOGICAL INFORMATION

Rat Oral LD 50 1580 mg/kg

FD&C Yellow No. 6; (Sunset yellow)

Rat Oral LD50 > 10,000 mg/kgOral Mouse > 6,000 mg/kgLD50

Citric acid, anhydrous

Oral LD50 3000 mg/kg

Glycerin, USP

Mouse Oral LD50 4090 mg/kg LD50 12.6 g/kg Oral Rabbit Dermal LD50 > 10 g/kgRat Inhalation LC50 1hr $> 570 \text{ mg/m}^3$ Rat Dermal LD 50 > 21.9 g/kg

Phenytoin

Mouse LD50 Oral 150 mg/kg Rat Oral LD50 1635mg/kg Rat Intravenous LD 50 96mg/kg >337mg/kg Rat IM LD 50 Rabbit Oral LD 50 >3000mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Page 8 of 13

Irritation / Sensitization: (Study Type, Species, Severity)

Ethyl alcohol (ethanol)

Severe Eve Irritation Rabbit Skin Irritation Rabbit Mild

Citric acid, anhydrous

Eve Irritation Rabbit Severe Skin Irritation Rabbit Mild

Glycerin, USP

Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium benzoate

10 Day(s) Rat Oral 27370 mg/kg LOAEL Liver, Blood 10 Day(s) Mouse Oral 45 g/kg LOAEL Liver, Kidney, Blood, Ureter, Bladder

Carboxymethylcellulose sodium

13 Week(s) LOAEL Liver, Kidney, Ureter, Bladder Rat Oral 227 g/kg

Phenytoin

PZ01947

Page 9 of 13

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

11. TOXICOLOGICAL INFORMATION

2 Week(s) Rat Oral <3125 ppm/day **NOEL** Bone marrow

2 Week(s) Mouse Oral <125 ppm/day NOEL Central Nervous System

13 Week(s) Rat Oral 300 ppm/day NOEL None identified

Oral 13 Week(s) 150 ppm/day Blood forming organs, Gastrointestinal system, Liver Mouse NOEL

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sodium benzoate

Embryo / Fetal Development Oral Rat 44 g/kg LOEL Developmental toxicity

Phenytoin

Embryo / Fetal Development Mouse Oral 75 mg/kg/day NOEL Maternal toxicity, Fetotoxicity, Teratogenic

Embryo / Fetal Development Mouse Oral 45 mg/kg/day **NOEL** Teratogenic

Fetotoxicity, Teratogenic Embryo / Fetal Development Rabbit Oral 50 mg/kg/day NOEL Embryo / Fetal Development Monkey Oral 10 mg/kg/day NOEL Fetotoxicity, Teratogenic

Embryo / Fetal Development Mouse Subcutaneous <12.5 mg/kg/day **NOEL** Maternal Toxicity, Fetotoxicity,

Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) Salmonella Negative

Phenytoin

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

In Vitro Chromosome Aberration **Human Lymphocytes** Negative In Vivo Sister Chromatid Exchange **Human Lymphocytes** Positive In Vivo Mitotic Spindle Assay **Human Lymphocytes** Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Phenytoin

2 Year(s) Male Rat Oral, in feed 50 mg/kg/day NOEL Benign neoplasms, Skin 2 Year(s) Mouse Oral, in feed 25 mg/kg/day NOEL Benign tumors, Liver 2 Year(s) Female Mouse Oral, in feed 60 ppm LOAEL Liver, neoplasms 2 Year(s) Female Rat Oral, in feed 240 ppm NOAEL Not carcinogenic

Carcinogen Status: See below

Ethyl alcohol (ethanol)

IARC: Group 1 (Carcinogenic to Humans)

FD&C Yellow No. 6; (Sunset yellow)

IARC: Group 3 (Not Classifiable)

Phenytoin

Group 2B (Possibly Carcinogenic to Humans) IARC: NTP: Reasonably Anticipated To Be A Human Carcinogen

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to

the environment should be avoided. See aquatic toxicity data, below:

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ethyl alcohol (ethanol)

Oncorhynchus mykiss (Rainbow Trout) LC50/96h 12,900-15,300 mg/L

Glycerin, USP

Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 50 mg/L

Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L

Phenytoin

Hyallela azteca (Freshwater Amphipod) OPPTS LC50 96 Hours 18 mg/L

Daphnia magna (Water Flea) TAD EC50 48 Hours >39 mg/L

Pimephales promelas (Fathead Minnow) OPPTS LC50 96 Hours >23 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum

solubility. Since the substance is insoluble in aqueous solutions above this concentration, an

Page 10 of 13

acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Ethyl alcohol (ethanol) Not Ready

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Phenytoin

Predicted 7.4 Log D 2.47

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Page 11 of 13

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018 Version: 2.1

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Carboxymethylcellulose sodium

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Citric acid, anhydrous

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

201-069-1

Concentrated orange oil

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling

Not Listed

Not Listed

Present

Present

Schedule 5

for Drugs and Poisons:

EU EINECS/ELINCS List Not Listed

Ethyl alcohol (ethanol)

CERCLA/SARA 313 Emission reporting Not Listed

California Proposition 65 carcinogen 4/29/2011 in alcoholic beverages

developmental toxicity 10/1/1987 in alcoholic beverages

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
200-578-6

FD&C Yellow No. 6; (Sunset yellow)

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Not Listed
Present

Material Name: Phenytoin Oral Suspension (Greenstone LLC)

Revision date: 05-Jun-2018

Page 12 of 13

Version: 2.1

15. REGULATORY INFORMATION

Australia (AICS): Present EU EINECS/ELINCS List 220-491-7

Glycerin, USP

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Not Listed
Present

Australia (AICS): Present

REACH - Annex V - Exemptions from the obligations of Register:Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC,

classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bio

accumulative, and toxic or very persistent and very bio accumulative in accordance with the criteria set out in Annex XIII,

except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent

level of concern

EU EINECS/ELINCS List 200-289-5

Imitation banana oil

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

Magnesium aluminum silicate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Eisted

Not Listed

Not

Phenytoin

CERCLA/SARA 313 Emission reporting 0.1 %

California Proposition 65 carcinogen 1/1/1988

developmental toxicity 7/1/1987

Australia (AICS): Present
Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 200-328-6

Polysorbate 40

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Purified water

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Not Listed

Not Listed

Present

Present

Material Name: Phenytoin Oral Suspension (Greenstone LLC) Page 13 of 13 Revision date: 05-Jun-2018 Version: 2.1

15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Sodium benzoate

CERCLA/SARA 313 Emission reporting Not Listed California Proposition 65 Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** 208-534-8

Sucrose

CERCLA/SARA 313 Emission reporting Not Listed Not Listed **California Proposition 65** Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **REACH - Annex IV - Exemptions from the** Present obligations of Register:

EU EINECS/ELINCS List 200-334-9

Vanillin

Not Listed **CERCLA/SARA 313 Emission reporting** Not Listed **California Proposition 65** Inventory - United States TSCA - Sect. 8(b) Present Present Australia (AICS): **EU EINECS/ELINCS List** 204-465-2

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Flammable liquids-Cat.2; H225 - Highly flammable liquid and vapor Reproductive toxicity-Cat.1B; H360D - May damage the unborn child Carcinogenicity-Cat.2; H351 - Suspected of causing cancer Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources,

raw material suppliers, or from the published literature.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on **Reasons for Revision:**

Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12

- Ecological Information.

Revision date: 05-Jun-2018

Product Stewardship Hazard Communication Prepared by: Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet